首页> 外文期刊>Saudi journal of kidney diseases and transplantation : >Comparative evaluation of efficacy and safety profile of rhubarb and α-keto analogs of essential amino acids supplementation in patients with diabetic nephropathy
【24h】

Comparative evaluation of efficacy and safety profile of rhubarb and α-keto analogs of essential amino acids supplementation in patients with diabetic nephropathy

机译:大黄和α-酮类似物补充必需氨基酸治疗糖尿病肾病的疗效和安全性比较

获取原文
           

摘要

To determine the efficacy and safety profile of rhubarb and α-keto analogs of essential amino acids supplementation in patients of diabetic nephropathy (DN), we studied 96 patients of DN attending a tertiary care center of the North India. The patients were randomly divided into three equal interventional groups. Group I (control) that received conservative management along with placebo, Group II (rhubarb) that received conservative management along with rhubarb capsule (350 mg, thrice daily), and Group III [keto amino acid (KAA)] that received conservative management along with α-keto analogs of essential amino acids (600 mg, thrice daily). The treatment was continued for 12 weeks. Clinical and biochemical parameters were assessed at 0, 4, 8, and 12 weeks of treatment. A progressive improvement in clinical features and biochemical parameters was seen in all three groups after 12 weeks of treatment. The KAA group showed more marked improvement in clinical features as well as biochemical parameters compared to the rhubarb group. There was a reduction in blood glucose, blood urea, serum creatinine, and 24 h total urine protein. There was an increase in hemoglobin, 24 h total urine volume, and glomerular filtration rate. There was no statistical difference between the rhubarb and KAA groups with respect to side effects (P > 0.05). Our study suggests that KAA is more effective than rhubarb as add-on therapy with conservative management in patients of DN.
机译:为了确定大黄和必需氨基酸补充大黄和α-酮类似物在糖尿病肾病(DN)患者中的疗效和安全性,我们研究了北印度三级护理中心的96名DN患者。将患者随机分为三个相等的干预组。第一组(对照组)与安慰剂一起接受保守治疗,第二组(大黄)与大黄胶囊(350 mg,每天三次)一起接受保守治疗,第三组[酮氨基酸(KAA)]在接受安慰剂的同时接受保守治疗含必需氨基酸的α-酮类似物(600毫克,每天三次)。治疗持续12周。在治疗的0、4、8和12周评估临床和生化指标。在治疗12周后,所有三个组的临床特征和生化参数均得到了逐步改善。与大黄组相比,KAA组在临床特征和生化指标方面显示出更明显的改善。血糖,血尿素,血清肌酐和24小时总尿蛋白降低。血红蛋白,24小时总尿量和肾小球滤过率增加。大黄和KAA组之间在副作用方面无统计学差异(P> 0.05)。我们的研究表明,在保守治疗中,对于DN患者,KAA比大黄更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号